首页> 外文期刊>Biopharmaceutics and Drug Disposition >Disposition of acamprosate in the rat: Influence of probenecid.
【24h】

Disposition of acamprosate in the rat: Influence of probenecid.

机译:阿坎酸在大鼠中的处置:丙磺舒的影响。

获取原文
获取原文并翻译 | 示例
           

摘要

The purpose of the present study was to investigate the disposition of acamprosate (calcium bis acetyl-homotaurine) in the rat. Initially, we studied the linearity of acamprosate disposition and the fraction of acamprosate excreted unchanged in the urine of the animals. Rats received 9.3, 36.6 or 73.3 mg/kg of the drug as an intravenous bolus. The statistical analysis of the pharmacokinetic parameters did not reveal any significant difference, indicating that acamprosate disposition was linear within the range of the doses assayed. On average, 95% of the administered dose was excreted unchanged in the urine of the animals in the 0-6 h post-administration period indicating that renal excretion is the main elimination route for this drug. Acamprosate was also administered by the intravenous route at three different constant infusion rates (2.65, 132.5 and 530 &mgr;g/min) in order to quantify total (Cl(t)) and renal (Cl(r)) plasma clearances at steady-state conditions. The mean Cl(r) values were, respectively, 4.60+/-0.42, 4.28+/-0.52 and 4.08+/-0.67 ml/min, practically equivalent to the Cl(t) values (4.78+/-0.38, 4.51+/-0.36 and 4.21+/-0.56 ml/min), confirming that the drug is mainly eliminated via renal excretion. Moreover, Cl(r) values were clearly higher than the glomerular filtration rate (2.61+/-0.26 ml/min), suggesting the existence of a highly efficient tubular secretion mechanism in the renal excretion of the drug. To confirm this hypothesis, two groups of rats were intravenously treated with probenecid (33.3 or 66.6 mg/kg) prior to acamprosate administration (9.3 mg/kg). Probenecid provoked a statistically significant dose-dependent reduction in the total clearance of acamprosate (from 5.8+/-0.7 ml/min in the control group to 2.6+/-0.1 ml/min in the animals treated with 66 mg/kg of probenecid) demonstrating the existence of a tubular secretion process on the renal excretion of acamprosate in the rat. Copyright 2002 John Wiley & Sons, Ltd.
机译:本研究的目的是研究大鼠中阿坎酸(双乙酰基-高尿酸钙)的处置。最初,我们研究了阿坎酸的线性分布以及阿坎酸在动物尿液中的排泄情况。大鼠静脉内推注9.3、36.6或73.3 mg / kg的药物。药代动力学参数的统计分析未发现任何显着差异,表明阿坎酸分布在所测定剂量范围内呈线性。平均而言,在给药后的0-6小时内,动物的尿液中95%的给药剂量被不变地排泄,表明肾脏排泄是该药物的主要消除途径。还通过静脉内途径以三种不同的恒定输注速度(2.65、132.5和530μg/ min)施用阿坎酸,以便定量测定稳态时总(Cl(t))和肾脏(Cl(r))的血浆清除率。状态条件。平均Cl(r)值分别为4.60 +/- 0.42、4.28 +/- 0.52和4.08 +/- 0.67 ml / min,实际上等于Cl(t)值(4.78 +/- 0.38,4.51+ /-0.36和4.21 +/- 0.56 ml / min),证实该药物主要通过肾脏排泄消除。此外,Cl(r)值明显高于肾小球滤过率(2.61 +/- 0.26 ml / min),表明在药物的肾脏排泄中存在高效的肾小管分泌机制。为了证实这一假设,在给予阿坎酸(9.3 mg / kg)之前,对两组大鼠进行丙磺舒(33.3或66.6 mg / kg)静脉内治疗。丙磺舒引起阿坎酸总清除率的统计学显着剂量依赖性降低(从对照组的5.8 +/- 0.7 ml / min降低到用66 mg / kg丙磺舒治疗的动物中的2.6 +/- 0.1 ml / min)证实肾小管阿坎酸的肾排泄中存在肾小管分泌过程。版权所有2002 John Wiley&Sons,Ltd.

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号